Literature DB >> 28061043

An Overview of R in Health Decision Sciences.

Hawre Jalal1, Petros Pechlivanoglou2, Eline Krijkamp3, Fernando Alarid-Escudero4, Eva Enns4, M G Myriam Hunink5.   

Abstract

As the complexity of health decision science applications increases, high-level programming languages are increasingly adopted for statistical analyses and numerical computations. These programming languages facilitate sophisticated modeling, model documentation, and analysis reproducibility. Among the high-level programming languages, the statistical programming framework R is gaining increased recognition. R is freely available, cross-platform compatible, and open source. A large community of users who have generated an extensive collection of well-documented packages and functions supports it. These functions facilitate applications of health decision science methodology as well as the visualization and communication of results. Although R's popularity is increasing among health decision scientists, methodological extensions of R in the field of decision analysis remain isolated. The purpose of this article is to provide an overview of existing R functionality that is applicable to the various stages of decision analysis, including model design, input parameter estimation, and analysis of model outputs.

Keywords:  R project; cost-effectiveness analysis; economic evaluation; literature review

Mesh:

Year:  2017        PMID: 28061043     DOI: 10.1177/0272989X16686559

Source DB:  PubMed          Journal:  Med Decis Making        ISSN: 0272-989X            Impact factor:   2.583


  29 in total

1.  "Time Traveling Is Just Too Dangerous" but Some Methods Are Worth Revisiting: The Advantages of Expected Loss Curves Over Cost-Effectiveness Acceptability Curves and Frontier.

Authors:  Fernando Alarid-Escudero; Eva A Enns; Karen M Kuntz; Tzeyu L Michaud; Hawre Jalal
Journal:  Value Health       Date:  2019-05       Impact factor: 5.725

Review 2.  A Comparison of Four Software Programs for Implementing Decision Analytic Cost-Effectiveness Models.

Authors:  Chase Hollman; Mike Paulden; Petros Pechlivanoglou; Christopher McCabe
Journal:  Pharmacoeconomics       Date:  2017-08       Impact factor: 4.981

3.  A Flexible Open-Source Decision Model for Value Assessment of Biologic Treatment for Rheumatoid Arthritis.

Authors:  Devin Incerti; Jeffrey R Curtis; Jason Shafrin; Darius N Lakdawalla; Jeroen P Jansen
Journal:  Pharmacoeconomics       Date:  2019-06       Impact factor: 4.981

4.  A cost-utility analysis of atezolizumab in the second-line treatment of patients with metastatic bladder cancer.

Authors:  A Parmar; M Richardson; P C Coyte; S Cheng; B Sander; K K W Chan
Journal:  Curr Oncol       Date:  2020-08-01       Impact factor: 3.677

5.  A Multidimensional Array Representation of State-Transition Model Dynamics.

Authors:  Eline M Krijkamp; Fernando Alarid-Escudero; Eva A Enns; Petros Pechlivanoglou; M G Myriam Hunink; Alan Yang; Hawre J Jalal
Journal:  Med Decis Making       Date:  2020-01-28       Impact factor: 2.583

6.  Estimated Quality of Life and Economic Outcomes Associated With 12 Cervical Cancer Screening Strategies: A Cost-effectiveness Analysis.

Authors:  George F Sawaya; Erinn Sanstead; Fernando Alarid-Escudero; Karen Smith-McCune; Steven E Gregorich; Michael J Silverberg; Wendy Leyden; Megan J Huchko; Miriam Kuppermann; Shalini Kulasingam
Journal:  JAMA Intern Med       Date:  2019-07-01       Impact factor: 21.873

Review 7.  Transparency in Decision Modelling: What, Why, Who and How?

Authors:  Christopher James Sampson; Renée Arnold; Stirling Bryan; Philip Clarke; Sean Ekins; Anthony Hatswell; Neil Hawkins; Sue Langham; Deborah Marshall; Mohsen Sadatsafavi; Will Sullivan; Edward C F Wilson; Tim Wrightson
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

8.  A Need for Change! A Coding Framework for Improving Transparency in Decision Modeling.

Authors:  Fernando Alarid-Escudero; Eline M Krijkamp; Petros Pechlivanoglou; Hawre Jalal; Szu-Yu Zoe Kao; Alan Yang; Eva A Enns
Journal:  Pharmacoeconomics       Date:  2019-11       Impact factor: 4.981

9.  Potential Bias Associated with Modeling the Effectiveness of Healthcare Interventions in Reducing Mortality Using an Overall Hazard Ratio.

Authors:  Fernando Alarid-Escudero; Karen M Kuntz
Journal:  Pharmacoeconomics       Date:  2020-03       Impact factor: 4.981

10.  Bioinformatics Analysis of a Prognostic miRNA Signature and Potential Key Genes in Pancreatic Cancer.

Authors:  Shuoling Chen; Chang Gao; Tianyang Yu; Yueyang Qu; Gary Guishan Xiao; Zunnan Huang
Journal:  Front Oncol       Date:  2021-05-20       Impact factor: 6.244

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.